ESMO 2022 Conference Coverage


 

ESMO 2022 on Outcomes of Real World Patients With Advanced NSCLC and High PD-L1 Expression Receiving 1L Immune Checkpoint Inhibitor Therapy

96 views
September 27, 2022
Comments 0
Login to view comments. Click here to Login